Related Experiment Video
Updated: Jun 24, 2026
Employing Transcranial Magnetic Stimulation in a Resource Limited Environment to Establish Brain-Behavior Relationships
Published on: April 20, 2022
Translational development strategy for magnetic seizure therapy
Stefan B Rowny1, Karla Benzl, Sarah H Lisanby
1Brain Stimulation and Therapeutic Modulation Division, Columbia University College of Physicians and Surgeons, New York State Psychiatric Institute, 1051 Riverside Drive, Unit 21, New York, NY 10032, USA. srowny@columbia.edu
Magnetic seizure therapy (MST) offers a novel approach to depression treatment, aiming to reduce cognitive side effects associated with electroconvulsive therapy (ECT) by inducing focal seizures. This strategy focuses on improving treatment outcomes and patient tolerability.
Area of Science:
- Neuroscience
- Psychiatry
- Biomedical Engineering
Background:
- Electroconvulsive therapy (ECT) demonstrates high antidepressant efficacy but is associated with persistent cognitive side effects.
- Emerging research suggests that cognitive side effects of ECT may be separable from its therapeutic benefits, potentially linked to distinct cortical networks.
- This dissociation opens avenues for therapeutic strategies that minimize side effects, such as focal seizure induction.
Purpose of the Study:
- To present the translational development strategy for Magnetic Seizure Therapy (MST) as a novel antidepressant treatment.
- To explore MST's potential to induce focal seizures, thereby minimizing cognitive side effects compared to ECT.
- To outline the iterative process of device development, preclinical testing, and clinical trials for MST.
Main Methods:
- A multi-stage translational development strategy was employed, including device engineering, animal feasibility studies, and nonhuman primate research.
- Nonhuman primate models were utilized for safety, mechanism of action studies (neuroanatomy, neurophysiology, cognition), and to validate cognitive assessment tools sensitive to ECT effects.
- Human safety and efficacy testing were conducted, alongside dosage optimization and plans for randomized comparisons with ECT.
Main Results:
- The development of MST involved iterative enhancements based on preclinical and early clinical findings.
- A nonhuman primate model of ECT and a validated monkey cognitive battery aided safety testing and understanding of cognitive effects.
- An international consortium facilitated human testing, focusing on technique and dose/response relationships.
Conclusions:
- MST represents a promising alternative to ECT for depression, with a development strategy focused on minimizing cognitive side effects through focal seizure induction.
- Continued research is necessary to fully characterize MST's dose/response relationships, optimize efficacy, and establish reliable methods for inducing lasting therapeutic changes in brain circuitry.
- Challenges include optimizing treatment parameters and ensuring the long-term effectiveness of MST in treating depression.
